Bio-Rad outlines 2026 margin expansion and 0.5%-1.5% revenue growth guidance amid operational improvements
Source: SeekingAlpha
2026-02-12 19:35:10 ET
More on Bio-Rad Laboratories, Inc.
- Bio-Rad Laboratories, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript
- Bio-Rad Laboratories Still Hampered By Underwhelming Core Growth
- Bio-Rad Laboratories, Inc. Q4 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Bio-Rad Laboratories, Inc.
Read the full article on Seeking Alpha
For further details see:
Bio-Rad outlines 2026 margin expansion and 0.5%-1.5% revenue growth guidance amid operational improvements
Bio-Rad Laboratories Inc. Class A
NASDAQ: BIO
BIO Trading
-0.48% G/L:
$269.59 Last:
104,506 Volume:
$268.20 Open:
BIO Latest News
January 29, 2026 08:30:00 am
Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
BIO Stock Data
$8,088,674,023
21,121,296
0.01%
179
N/A
Biotechnology & Life Sciences
Healthcare
US
Hercules
